The FDA deleted its most viral pandemic-era social media campaign — including the infamous “You are not a horse” posts — after losing in federal court.
Three Texas doctors forced the agency to remove consumer warnings that many argued crossed the line from public health messaging into unauthorized medical practice.
When the U.S. Food and Drug Administration quietly erased years of aggressive social media warnings against ivermectin in March 2024, it was not an admission that the Nobel Prize-winning drug worked against COVID-19. It was a legal concession that the agency had overstepped its authority by effectively practicing medicine through tweets and consumer alerts. The move followed a hard-fought lawsuit by three doctors who argued the FDA’s “You are not a horse” campaign damaged their practices and interfered with the doctor-patient relationship.
This is the story of that retreat — and what it reveals about institutional power, pharmaceutical incentives, scientific debate, and the quiet rise of ivermectin in another arena: cancer research and patient-driven protocols.
The Legal Victory That Forced the FDA’s Hand
In June 2022, three Texas physicians — Dr. Robert Apter, Dr. Mary Talley Bowden, and Dr. Paul Marik — sued the FDA, HHS, and agency officials. They claimed the FDA’s social media posts and website warnings against using ivermectin for COVID-19 constituted unlawful interference with the practice of medicine. The posts, including the viral August 2021 tweet “You are not a horse. You are not a cow. Seriously, y’all. Stop it,” had become cultural shorthand and were blamed for pharmacies refusing legitimate prescriptions and state medical boards targeting doctors.
In March 2024 the parties reached a settlement. The FDA agreed to delete the specific consumer update and all related social media posts on X (Twitter), Facebook, Instagram, and LinkedIn within 21 days and to refrain from republishing them. The agency did not change its official position that “currently available clinical trial data do not demonstrate that ivermectin is effective against COVID-19.”
This distinction matters. The victory was procedural and constitutional — the FDA cannot give individualized medical advice disguised as public health messaging — rather than a scientific vindication of efficacy. Yet the optics of a federal agency deleting its own pandemic-era content after losing in court sent a powerful signal to millions who felt gaslit during the height of the crisis.
What Was Actually Removed — And What Wasn’t
The deleted content included the March 2021 consumer update “Why You Should Not Use Ivermectin to Treat or Prevent COVID-19” and the three most infamous social posts. These had been viewed tens of millions of times. The FDA’s current page on ivermectin and COVID-19 (updated as recently as April 2024) still states clearly that the drug is not authorized or approved for that use and that clinical data do not support effectiveness.
Every single corporate media outlet owes Joe Rogan and Ivermectin an apology for years of misinformation. pic.twitter.com/QtHCR3jhAV
— Mythinformed (@MythinformedMKE) August 16, 2023
Ivermectin: A Nobel Prize-Winning Drug With an Extraordinary Safety Record
Before it became a culture-war flashpoint, ivermectin was celebrated as one of the most important drugs in modern medicine. Discovered by Satoshi Ōmura and William C. Campbell, it earned them (and the drug) a share of the 2015 Nobel Prize in Physiology or Medicine for transforming the treatment of river blindness (onchocerciasis) and lymphatic filariasis. Billions of doses have been distributed through programs like the Mectizan Donation Program, dramatically reducing suffering in some of the world’s poorest regions.
Chemically, ivermectin is a macrocyclic lactone derived from Streptomyces avermitilis. In parasites it potentiates glutamate-gated chloride channels, causing paralysis. In mammals the same channels have much lower affinity, which is why therapeutic doses are generally well tolerated. The drug has been FDA-approved for human use since the late 1980s for specific parasitic indications. Its safety profile at approved doses is among the best documented of any antiparasitic agent.
This long track record of safety at standard doses is precisely why many physicians and patients found the “horse paste” framing during the pandemic so jarring — and why the alternative narrative of deliberate demonization gained traction.
The COVID-19 Chapter: Where Evidence and Incentives Collided
Early in the pandemic, laboratory studies showed ivermectin could inhibit SARS-CoV-2 replication in vitro. Some small observational studies and meta-analyses suggested clinical benefit, particularly in early treatment or prophylaxis. Doctors in the FLCCC Alliance (including Dr. Pierre Kory and Dr. Paul Marik) developed protocols combining ivermectin with other repurposed agents and reported positive outcomes in their practices.
However, large, high-quality randomized controlled trials — including the UK PRINCIPLE trial, the U.S. ACTIV-6 trial, and the TOGETHER trial in Brazil — generally found no statistically significant benefit on key outcomes such as hospitalization or death when ivermectin was used at standard antiparasitic doses in outpatient settings. A 2022 Cochrane review reached similar conclusions. Critics of these trials argue that many enrolled patients late in disease course, used doses too low for antiviral effect, or had other methodological limitations. Supporters of the official position counter that the totality of rigorous evidence does not support routine use.
Unspoken tensionUnder FDA rules for Emergency Use Authorization, there must be “no adequate, approved, and available alternative” to the authorized product. Widespread acceptance of a cheap, generic, long-approved drug like ivermectin as effective against COVID-19 would have complicated — or potentially blocked — the EUA pathway for novel vaccines and therapeutics that generated tens of billions in revenue and carried liability protection under the PREP Act. Whether this created institutional bias is debated; that the structural incentive existed is a matter of public record.
During the height of the pandemic, many doctors who prescribed ivermectin off-label faced professional repercussions. Pharmacies refused prescriptions. Social media platforms removed content. The FLCCC doctors and others were heavily censored. The 2024 settlement and the 5th Circuit ruling later validated the argument that at least some of the FDA’s public communications had crossed a legal line.
Ivermectin and Cancer: Preclinical Promise Meets Anecdotal Demand
Parallel to the COVID debate, a separate body of research has explored ivermectin’s potential anti-cancer properties. Multiple preclinical (cell line and animal) studies have shown that ivermectin can inhibit proliferation, induce apoptosis, and modulate pathways such as Wnt/β-catenin, Akt/mTOR, and PAK1 in various cancer models. One frequently cited 2020 review in PMC summarized these mechanisms.
In early 2025, actor Mel Gibson discussed a combination of ivermectin and fenbendazole (or mebendazole) on The Joe Rogan Experience as having helped friends with cancer. Prescriptions for the combination surged, particularly among cancer patients, according to a May 2026 study published in JAMA Network Open. Some states expanded access to ivermectin, making it available over-the-counter or behind-the-counter.
Patient testimonials continue to circulate on social media — stories of stage IV diagnoses, failed conventional treatment, and subsequent remission attributed to ivermectin-based or ivermectin + fenbendazole protocols. One widely shared example from 2025:
“My doctors told me I was ‘incurable’ at 32 with Stage 4 cancer. They failed me. So I looked elsewhere. I started a Fenbendazole & Ivermectin protocol. Today, I celebrate 1 YEAR of being completely CANCER-FREE. Never let anyone tell you it’s over.”— Patient testimonial widely shared on X
These stories are emotionally powerful and fuel demand. Rigorous science, however, requires randomized, controlled data. The gap between promising lab results and proven clinical outcomes remains significant for cancer — just as it did (and largely still does) for COVID-19.
Why Mainstream Media and Many Fact-Checkers Stayed Largely Silent
The March 2024 settlement received coverage in outlets across the spectrum — CNN, Newsweek, The Texan, Politico, and conservative sites. Yet the broader implications were often downplayed or framed narrowly as a “procedural win” rather than evidence of earlier institutional overreach. Several dynamics explain the relative quiet:
- Narrative lock-in: For years the dominant story was that ivermectin was a dangerous veterinary drug promoted by fringe actors. Admitting the FDA had gone too far in its messaging risked undermining that narrative.
- Regulatory consensus vs. emerging data: Fact-checking organizations and legacy media heavily weighted statements from FDA, CDC, WHO, and major medical societies. Dissenting meta-analyses or observational data from frontline doctors were frequently labeled “misinformation” even when later court records showed problems with agency communications.
- Institutional incentives: During the pandemic, novel vaccines and therapeutics enjoyed liability protection and massive public investment. Acknowledging a cheap, repurposed alternative with a long safety record could have complicated policy, procurement, and public messaging.
- Polarization: Ivermectin became politically charged early on. Coverage often followed tribal lines rather than nuanced examination of trial design, timing of treatment, or dosing questions.
The result was a chilling effect on open scientific debate at the exact moment when rapid learning was most needed. The 2024 settlement and the 5th Circuit’s blunt language (“The FDA is not a physician”) exposed the cost of that approach.
Real People, Real Stakes
Beyond court filings and trial abstracts are human beings who made difficult choices under fear and uncertainty. Some credit ivermectin (alone or in combination) with recovery from COVID when standard protocols offered little. Others with advanced cancer report stability or remission after exploring repurposed protocols when conventional options were exhausted or intolerable.
These experiences do not constitute proof. They do constitute signal — the kind of real-world data that historically has sometimes preceded formal trials (and sometimes proven misleading). Dismissing them entirely as “anecdote” while simultaneously acknowledging that large trials can miss subgroup effects or early-treatment windows is intellectually inconsistent.
Latest Developments (2025–2026)
The story has not ended. In June 2025, America’s Frontline Doctors (AFLDS) filed a citizen petition asking the FDA to reclassify ivermectin tablets as over-the-counter for both approved parasitic indications and for COVID-19 prophylaxis/early treatment. Several states — Tennessee, Arkansas, Idaho, and Louisiana — have passed laws making human ivermectin more accessible without prescription. Celebrity discussion in early 2025 triggered measurable increases in prescriptions for cancer-related use, prompting new preclinical interest at the National Cancer Institute.
Meanwhile, the core scientific questions remain open: optimal dosing and timing for any antiviral effect, potential synergy with other agents, long-term safety at higher doses used in some protocols, and rigorous evaluation in oncology. The legal precedent from 2024 stands: federal health agencies cannot simply tell Americans what medicine they may or may not take when that crosses into practicing medicine.
Medical Freedom, Institutional Trust, and the Search for Truth
The FDA’s 2024 retreat on ivermectin was a narrow legal victory, not a blanket endorsement. It did, however, expose how aggressively the agency had policed a long-approved, Nobel-recognized molecule during a crisis — and how thin the legal and scientific ground for some of that policing ultimately proved to be.
For patients and physicians who felt their judgment was overridden by centralized messaging, the settlement was vindication of a principle: doctors, not tweets, should guide individual care. For those who maintain that the large trials were definitive and that self-medication remains risky, the episode is a reminder that even well-intentioned public health communication can cause collateral damage when it becomes coercive.
The rise of patient interest in ivermectin for cancer adds another layer. Preclinical signals exist. Anecdotes abound. Formal proof does not — yet. The responsible path is accelerated, transparent clinical research rather than reflexive dismissal or uncritical promotion.
In the end, the lesson is older than the pandemic: institutions lose trust when they appear more interested in protecting narratives than in pursuing evidence wherever it leads. The 2024 settlement was one small correction. Whether it leads to a broader recalibration remains to be seen.
My doctors told me I was "incurable" at 32 with Stage 4 cancer. They failed me.
— Commentary | Global Ivermectin Research Hub (@Ivermectinkart) June 25, 2026
So I looked elsewhere.
I started a Fenbendazole & Ivermectin protocol.
Today, I celebrate 1 YEAR of being completely CANCER-FREE.
Never let anyone tell you it's over. pic.twitter.com/YWUfyWZvRZ
Primary Sources & Further Reading
- • Gateway Pundit — FDA Loses Its War on Ivermectin (March 2024)
- • 5th Circuit Court of Appeals opinion (September 2023)
- • FDA settlement agreement & current consumer update page (April 2024)
- • AFLDS Citizen Petition for OTC Ivermectin (June 2025)
- • PMC7505114 — Ivermectin anti-cancer mechanisms review
- • JAMA Network Open (May 2026) — Ivermectin-benzimidazole prescribing surge study
- • Ongoing TNBC Phase 1/2 trial NCT05318469 (Cedars-Sinai)
- • Nobel Prize 2015 official release for avermectin/ivermectin